AZ-SUPIMA/TEXTILEGENESIS
13.6.2022 10:02:09 CEST | Business Wire | Press release
Supima, the brand for American-grown Pima cotton, announces a strategic partnership with TextileGenesis™ to establish the new industry benchmark platform for authenticating cotton.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005099/en/
The Supima blockchain platform powered by TextileGenesis™ will digitally connect Supima’s comprehensive supply chain from the growers to the brand/retailers. Integrated with this digital platform, Supima’s technology partner Oritain™ will provide the forensic origin authentication for Supima cotton across the platform. The ability to independently validate the Supima content of products at every stage of the supply chain achieves unmatched authenticity and responsibility through the combination of forensic physical and digital authentication.
Since it was founded in 1954, SUPIMA® has been referred to as the “world’s finest cottons.” Today marks the next chapter in Supima’s ongoing leadership role in bringing the most trusted and robust verification solution to authentic premium fiber sourcing to the global fashion industry. SUPIMA® is fortunate to partner with brands and retailers that are leaders in transparency and responsible sourcing. This ground-breaking supply chain traceability platform will provide an underlying mechanism to collaborate with the partners in a transparent, and verifiable way.
TextileGenesis’ Fibercoin™ technology will be integrated into Supima’s licensing program and applied to all SUPIMA® branded fiber throughout the supply chain, creating a non-fungible digital token for every kilogram of Supima cotton that can be physically and forensically verified and authenticated by Supima from the farm through to the retail shelf. This pioneering effort for cotton sourcing sets a new standard for responsibility in the global textile industry and consumer marketplace. Supima is striving to bring deeper levels of authenticity and responsibility to cotton sourcing with greater support for equity and ubiquity for all partners in the supply chain.
“The Supima partnership with TextileGenesis provides for the very first time, undisputable proof of origin for consumer products all the way back to the fiber’s origin. This enables Supima’s partner brands to credibly claim advantages in terms of product quality and sustainability that are independently verifiable through both digital and forensic testing. There is no system like this for any other fiber. SUPIMA® partners will have the most authentic and trustworthy premium cotton source for all the current and future needs of luxury apparel and home textile products,” says Marc Lewkowitz, President and CEO of Supima.
“This collaboration is setting a new benchmark for the cotton and premium fiber’s industry, and paves a new path for the entire fashion eco-system. We are creatively combining three major innovations - digital-tokens based article-level traceability, forensic physical verification, and Supima brand-licensing - in a single integrated platform. It creates a new platinum standard in the industry for end-to-end traceability and physical verification,” says Amit Gautam, Founder and CEO of TextileGenesis.
ABOUT TEXTILEGENESIS
TextileGenesis is a market-leading traceability platform custom-built for the fashion and textile ecosystem. It has partnered with 40+ leading global brands to create fiber-to-retail traceability for sustainable, premium and certified materials. By the end of 2022, TextileGenesis will create traceability for 500 million+ units in the global fashion industry.
ABOUT SUPIMA
Supima is America’s luxury cotton: founded in 1954, the Supima brand, short for “Superior Pima,” designates an exclusive source of exceptional extra-long staple cotton responsibly grown only in the West and the Southwestern U.S. It is prized the world over by designers and discerning consumers who value its resilient strength, lasting color, indulgent softness, and durability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom